Capricor Therapeutics (NASDAQ:CAPR) Stock Rating Reaffirmed by HC Wainwright
HC Wainwright reiterated their buy rating on shares of Capricor Therapeutics (NASDAQ:CAPR – Free Report) in a report published on Tuesday, Benzinga reports. HC Wainwright currently has a $40.00 price target on the biotechnology company’s stock. Capricor Therapeutics Price Performance Shares of CAPR stock opened at $5.05 on Tuesday. Capricor Therapeutics has a 12-month low […]
21 Sep 07:09 · The Markets Daily